BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 23617429)

  • 1. Boron chemicals in diagnosis and therapeutics.
    Das BC; Thapa P; Karki R; Schinke C; Das S; Kambhampati S; Banerjee SK; Van Veldhuizen P; Verma A; Weiss LM; Evans T
    Future Med Chem; 2013 Apr; 5(6):653-76. PubMed ID: 23617429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focusing on boron in medicinal chemistry.
    Ramachandran PV
    Future Med Chem; 2013 Apr; 5(6):611-2. PubMed ID: 23617421
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and marketed proteasome inhibitors for cancer treatment.
    Zhang J; Wu P; Hu Y
    Curr Med Chem; 2013; 20(20):2537-51. PubMed ID: 23531219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Boron in drug design: Recent advances in the development of new therapeutic agents.
    Fernandes GFS; Denny WA; Dos Santos JL
    Eur J Med Chem; 2019 Oct; 179():791-804. PubMed ID: 31288128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibitors.
    Cvek B
    Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib for the treatment of non-Hodgkin's lymphoma.
    Bose P; Batalo MS; Holkova B; Grant S
    Expert Opin Pharmacother; 2014 Nov; 15(16):2443-59. PubMed ID: 25263936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
    Huber EM; Groll M
    Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting bortezomib: development, application, adverse effects and future direction.
    Cao B; Li J; Mao X
    Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietary Flavonoids with Catechol Moiety Inhibit Anticancer Action of Bortezomib: What about the other Boronic Acid-based Drugs?
    Sak K
    Curr Cancer Drug Targets; 2022; 22(9):741-748. PubMed ID: 35578889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular targeting agents for multiple myeloma].
    Fujii S; Abe M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
    [No Abstract]   [Full Text] [Related]  

  • 11. Discovery, Development, and clinical applications of bortezomib.
    Jung L; Holle L; Dalton WS
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Proteasome inhibitor].
    Yagi H
    Nihon Rinsho; 2014 Jun; 72(6):1125-9. PubMed ID: 25016815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Not boring at all. Boron is the new carbon in the quest for novel drug candidates.
    Hunter P
    EMBO Rep; 2009 Feb; 10(2):125-8. PubMed ID: 19182828
    [No Abstract]   [Full Text] [Related]  

  • 14. The ubiquitin proteasome pathway from bench to bedside.
    Orlowski RZ
    Hematology Am Soc Hematol Educ Program; 2005; ():220-5. PubMed ID: 16304384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
    Broyl A; Jongen JL; Sonneveld P
    Semin Hematol; 2012 Jul; 49(3):249-57. PubMed ID: 22726548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
    Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib for the treatment of multiple myeloma.
    Grosicki S; Barchnicka A; Jurczyszyn A; Grosicka A
    Expert Rev Hematol; 2014 Apr; 7(2):173-85. PubMed ID: 24617331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibitor therapy in multiple myeloma.
    Chauhan D; Hideshima T; Mitsiades C; Richardson P; Anderson KC
    Mol Cancer Ther; 2005 Apr; 4(4):686-92. PubMed ID: 15827343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Proteasome inhibitors in treatment of multiple myeloma].
    Kubiczková L; Matějíková J; Sedlaříková L; Kryukov F; Hájek R; Sevčíková S
    Klin Onkol; 2013; 26(1):11-8. PubMed ID: 23528167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibitors in the treatment of B-cell malignancies.
    Schenkein D
    Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.